Cesca Therapeutics Announces Financial Results for the Transition Period July 1, 2017 to December 31, 2017

Genetics Investing

Cesca Therapeutics (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced financial and operating results for the transition period from July 1, 2017 to December 31, 2017, which is necessary to accommodate the change in the Company’s fiscal year end from June 30 to December 31, and provided a …

Cesca Therapeutics (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced financial and operating results for the transition period from July 1, 2017 to December 31, 2017, which is necessary to accommodate the change in the Company’s fiscal year end from June 30 to December 31, and provided a corporate update.

As quoted in the press release:

  • On March 19, 2018, Cesca’s ThermoGenesis device subsidiary filed a new patent application with the US Patent and Trademark Office (USPTO) for an innovation to its CAR-TXpress™ technology which will allow for the simultaneous purification and activation of T-cells, thereby simplifying the CAR-TXpress workflow and tangibly accelerating the CAR-T cell manufacturing process.
  • Also on March 19, the Company announced that ThermoGenesis signed an exclusive license agreement with China-based IncoCell Tianjin Ltd. for CAR-T related contract development and manufacturing (CDMO) services covering the Asia Pacific region.

Click here to read the full press release.

The Conversation (0)
×